Phase 1 Start
RADX: Phase 1 Start: A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Mono
October 30, 2026 · nth-2403. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 30, 2026
- Company
- Radiopharm Theranostics Limited (RADX)
- Drug
- nth-2403
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 1 Start~month
Phase 1 Start: A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Mono
- Drug
- nth-2403
- Indication
- Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer